Iron supplementation timing and efficacy of erythropoiesis in hemodialysis patients receiving epoetin beta pegol: a randomized controlled study

Iron supplementation timing and efficacy of erythropoiesis in hemodialysis patients receiving epoetin beta pegol: a randomized controlled study - Iron supplementation timing and efficacy of erythropoiesis in hemodialysis patients receiving epoetin beta pegol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016375

Enrollment

200

Registered

2015-01-29

Start date

2015-01-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

Iron supplementation following epoetin beta pegol administration Iron supplementation two weeks after epoetin beta pegol administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with maintenance hemodialysis (2) Patients with renal anemia, who are treated with rHuEPO or iron

Exclusion criteria

Exclusion criteria: (1) Patients with chronic inflammation, malignant disorder, severe congestive heart failure, respiratory organs, and liver disorder (2) Patients who are receiving dialysis modalities other than hemodialysis

Design outcomes

Primary

Measure	Time frame
(1) Hemoglobin and erythropoiesis-related indexes (2)Blood chemical examination including iron-related, inflammation, nutrition indexes (3)Required dose of epoetin beta pegol (4)Hemodynamic parameters (5)Prognosis	—

Countries

Japan

Contacts

Public ContactTomoyuki Kawano

Bunko Jin Clinic Director /Director of hemodialysis clinic

t-kawano@kousai.or.jp045-790-8280

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026